Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E24.81 EPS (ttm)1.83 Insider Own16.40% Shs Outstand2.60B Perf Week2.23%
Market Cap118.06B Forward P/E14.00 EPS next Y3.24 Insider Trans0.00% Shs Float2.35B Perf Month5.66%
Income4.74B PEG3.54 EPS next Q- Inst Own10.70% Short Float0.21% Perf Quarter14.90%
Sales37.42B P/S3.16 EPS this Y1.40% Inst Trans-0.83% Short Ratio2.81 Perf Half Y19.22%
Book/sh24.13 P/B1.88 EPS next Y5.71% ROA- Target Price47.00 Perf Year18.32%
Cash/sh- P/C- EPS next 5Y7.00% ROE- 52W Range36.81 - 45.49 Perf YTD12.14%
Dividend1.58 P/FCF- EPS past 5Y-4.60% ROI6.20% 52W High-0.31% Beta0.99
Dividend %3.48% Quick Ratio1.20 Sales past 5Y-0.20% Gross Margin69.20% 52W Low23.20% ATR0.57
Employees106859 Current Ratio1.60 Sales Q/Q3.30% Oper. Margin- RSI (14)71.57 Volatility1.05% 0.93%
OptionableYes Debt/Eq0.32 EPS Q/Q12.90% Profit Margin- Rel Volume1.28 Prev Close45.38
ShortableYes LT Debt/Eq0.29 EarningsFeb 08 BMO Payout- Avg Volume1.72M Price45.35
Recom1.70 SMA203.01% SMA506.84% SMA20012.07% Volume2,212,614 Change-0.07%
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Mar-28-17 09:08PM  [$$] FDA Approves Regeneron and Sanofis Dupixent for Eczema at The Wall Street Journal
08:45PM  Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen
05:19PM  FDA approves Sanofi Genzyme drug amid questions over patent, cost at
04:38PM  Regeneron, Sanofi Get Approval For Eczema Drug Priced At $37,000
04:16PM  Regeneron, Sanofi Score Eczema Drug Approval
01:56PM  FDA approves Regeneron, Sanofi $37,000 per year eczema drug Reuters
01:50PM  Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval PR Newswire
12:11PM  [$$] FDA Approves Regeneron and Sanofi's Dupixent for Eczema at The Wall Street Journal
11:54AM  Regeneron, Sanofi announce FDA approval of atopic dermatitis treatment at MarketWatch
11:40AM  Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis PR Newswire
11:40AM  Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis PR Newswire
11:38AM  FDA approves Regeneron, Sanofi eczema drug Reuters
11:11AM  VIVUS to Regain Commercial Rights for Stendra from Sanofi
10:37AM  How Mercks Animal Health Segment Performed in 2016
07:37AM  GlaxoSmithKlines Valuation Compared to Its Peers
Mar-27-17 11:45AM  Pfizer Rheumatoid Arthritis Drug Approved in EU at Investopedia
08:54AM  Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi at MarketWatch
08:54AM  Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Mar-26-17 09:03AM  3 Tremendously Promising Diabetes Drugs Potentially on the Way at Motley Fool
Mar-25-17 06:00AM  Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin Business Wire
Mar-24-17 04:19PM  Sanofi Could Acquire This Biotech, But Is $1 Billion Too Low?
10:13AM  Big Decision Week for Roche, GSK, Sanofi, Mylan at Investopedia
07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
Mar-23-17 05:36PM  Did Sanofi Just Bag This Biotech For $1 Billion?
04:36PM  Here's Why Flexion Therapeutics Inc. Skyrocketed Today at Motley Fool
03:37PM  Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout
02:07PM  Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
01:47PM  Flexion tops $800M in market cap on Sanofi buyout rumor at
11:25AM  Sanofi Said to Be Near $1 Billion Deal for Flexion
10:00AM  Merck Closes Acquisition of Controlling Stake in Vallee S.A
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
07:21AM  Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Reuters
Mar-22-17 09:40AM  Will Sanofi (SNY) Prove to be a Suitable Value Stock?
07:30AM  Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education PR Newswire
Mar-21-17 04:54PM  Sanofi and Regeneron Sue Amgen over Eczema Drug at Investopedia
04:35PM  Why AstraZenecas Brilinta Could Become a Blockbuster Drug in 2017
04:23PM  Could MannKind Corporation's Marketing Blitz Pay Off? at Motley Fool
02:45PM  Sanofi-Genzyme files preemptive legal strike to protect eczema drug at
12:33PM  Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims
07:30AM  Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S. PR Newswire
07:00AM  Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks at Morningstar
01:14AM  [$$] Sanofi's Prescription for Growth: Drug Sales in the Middle Kingdom at The Wall Street Journal
Mar-20-17 10:26AM  Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
Mar-17-17 04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
01:00PM  Amgen's Repatha Reduced Heart Attack, Stroke Risk at Investopedia
09:37AM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
09:30AM  The Zacks Analyst Blog Highlights: U.S. Bancorp, Verizon, EOG Resources, Sanofi and Nokia
08:48AM  What are Sanofi's (SNY) Strengths and Challenges in 2017?
Mar-16-17 04:04PM  New Stock Research Reports for Verizon, EOG, and U.S. Bancorp
Mar-15-17 02:48PM  Sanofi, Regenerons Dupilumab Gets UK Early Access at Investopedia
12:40PM  Bernie Sanders Slams Sanofi Zika Vaccine Deal at Investopedia
10:03AM  Sanofi and Voluntis Ink Global Pact for Diabetes at Investopedia
Mar-14-17 10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
05:46AM  Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes PR Newswire
05:10AM  UK gives early green light to Sanofi eczema drug Reuters
04:30AM  UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA PR Newswire
01:00AM  England Says No to Drugs That Cost More Than Your Car (or Home)
Mar-13-17 04:37PM  Amgen Tops Heart Study As Rivals Regeneron, Sanofi Chill In Court
02:50PM  Whats that thing on top of the Sanofi-Genzyme building anyway? at
01:37PM  Bernie Sanders lashed out at a drug company over potentially profiting from Zika
12:12PM  3 Companies That Probably Won't Survive Till 2019 at Motley Fool
Mar-10-17 10:28AM  Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?
Mar-09-17 01:04PM  SANOFI Financials
08:49AM  Coverage initiated on Sanofi by Liberum
Mar-08-17 10:35AM  Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
08:34AM  Sanofi gears up for European generic drugs unit sale - sources
12:31AM  Novo Seen Missing Target of 40 Million Diabetics Treated by 2020
Mar-07-17 08:00AM  Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions PR Newswire
07:04AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis at Motley Fool
Mar-06-17 02:28PM  Lexicon: On Its Way to Building Competitive Advantages
11:03AM  MedImmune, Sanofi ink deal worth up to $524.6M for RSV drug at
09:47AM  Sanofi :SNY-US: Earnings Analysis: For the six months ended December 31, 2016 : March 6, 2017
09:30AM  The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
12:16AM  [$$] New Jersey Complex, Once Owned by a Drug Giant, Becomes a Home for Many at The Wall Street Journal
Mar-04-17 12:07PM  Sanofi, Regeneron say latest Dupixent eczema drug tests positive Reuters
10:30AM  Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis PR Newswire
07:00AM  [$$] New Jersey Complex Finds New Life as a Home for Several Firms at The Wall Street Journal
Mar-03-17 04:42PM  Award-Winning International Fund Manager David Herro Picks 3 Stocks
02:01AM  Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV GlobeNewswire
12:05AM  [$$] Actelion Began in a GarageNow Its Founding Couple Has $1 Billion and a New Biotech Firm at The Wall Street Journal
Mar-02-17 01:15PM  Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA at Insider Monkey
09:30AM  Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
09:06AM  Dupixent Could Demonstrate Efficacy across Multiple Indications in 2017
07:37AM  Dupixent May Help Diversify Regenerons Revenues in 2017
07:00AM  [$$] Actelion's Founders Start New Biotech, With J&J's Backing at The Wall Street Journal
Mar-01-17 09:07AM  Regeneron Expected to Witness Robust Growth in Revenues in 2017
08:12AM  Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
Feb-28-17 11:03AM  3 Stocks to Avoid in Biotech at Motley Fool
10:37AM  Januvia, Vaccines May Drive Mercks Revenue Growth in 2017
09:55AM  Amicus Therapeutics Launches Galafold in UK at Investopedia
08:00AM  Kevzara (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis CNW Group
Feb-27-17 01:05PM  Sanofi, Lonza to Build $285M Biologics Plant at Investopedia
09:22AM  Sanofi's Base Pattern Should Make Investors Happy
08:30AM  Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses PR Newswire
08:30AM  Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses PR Newswire
Feb-25-17 11:42AM  BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster at Motley Fool
Feb-24-17 07:36AM  Merck & Co.s Animal Health Segment
Feb-23-17 05:06PM  Teva Is Expected to See a Fall in Its Profit Margins in 2017
Feb-22-17 09:20PM  Ipswich consultants biotech training program expands into Europe at
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM